COR vs ELV

Cencora (COR) trades at a premium valuation with strong 5-year price performance (+271.1%) and solid earnings growth (YoY EPS +15.0%), supported by consistent quarterly beats (22 of 25 quarters) and improving margins. However, its profitability metrics remain weak relative to peers—particularly gross margin (3.51%) and operating margin (1.14%)—while elevated leverage (Debt/Equity 4.38) and deteriorating liquidity (Current Ratio 0.90) raise structural concerns. The stock is priced for perfection with a P/E of 45.47, well above the sector average of 36.87, despite lower-than-peer revenue growth (5.9% vs 10.5%). Notably, recent insider selling totaling $18.51M over the past six months contrasts with a bullish analyst consensus, creating a mixed signal that tempers enthusiasm.

Elevance Health presents a complex value proposition characterized by a weak Piotroski F-Score of 3/9, indicating deteriorating fundamental health. While the stock is objectively undervalued, trading below its Graham Number ($340.31) and significantly below its intrinsic value ($763.75), recent financial performance is concerning with a -44.8% Q/Q EPS decline. The combination of bearish technicals and insider selling offsets the attractive valuation and strong analyst buy ratings. Consequently, the stock appears to be in a transition phase where deep value meets fundamental weakness.